Stockscreener 앱 받기
0.4151
7.69%
-0.0346
시간 외 거래:
.41
-0.0051
-1.23%
전일 마감가:
$0.4497
열려 있는:
$0.45
하루 거래량:
1.53M
Relative Volume:
0.85
시가총액:
$102.05M
수익:
$9.10M
순이익/손실:
$-82.47M
주가수익비율:
-0.7157
EPS:
-0.58
순현금흐름:
$-72.32M
1주 성능:
-7.18%
1개월 성능:
+23.36%
6개월 성능:
-43.28%
1년 성능:
-43.05%
1일 변동 폭
$0.4015
$0.4599
1주일 범위
$0.3899
$0.475
52주 변동 폭
$0.285
$1.07
Vaxart Inc Stock (VXRT) Company Profile
명칭
Vaxart Inc
전화
(650) 550-3500
주소
170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
VXRT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VXRT
Vaxart Inc
|
0.4151 | 102.05M | 9.10M | -82.47M | -72.32M | -0.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxart Inc Stock (VXRT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-15 | 개시 | Oppenheimer | Outperform |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-11-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-29 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-06-24 | 개시 | Jefferies | Buy |
| 2021-06-11 | 개시 | Piper Sandler | Overweight |
| 2020-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-13 | 개시 | B. Riley FBR | Buy |
모두보기
Vaxart Inc 주식(VXRT)의 최신 뉴스
Vaxart Resumes COVID-19 Vaccine Trial After Government Lift - TipRanks
Vaxart (VXRT) Advances Vaccine Efforts Amid Market Challenges | VXRT Stock News - GuruFocus
Vaxart seeks stockholder approval for reverse split - Investing.com
Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress - The Manila Times
Vaxart CEO Letter: Government Lifts Trial Hold, Norovirus Study Fully Enrolled, Cash Extended to 2026 - Stock Titan
Vaxart to Host First Quarter 2025 Business Update and Financial - GuruFocus
Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13 - GlobeNewswire
Vaxart, Inc. to Host Conference Call for Q1 2025 Financial Results on May 13, 2025 - Nasdaq
Vaxart Sets Q1 2025 Earnings Call Date: How to Join the May 13 Investor Update - Stock Titan
Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate - GlobeNewswire
Vaxart to Present at the Citizens Life Sciences Conference - GlobeNewswire
Exclusive: Vaxart Leadership Takes Stage at Citizens Life Sciences ConferenceKey Updates Expected - Stock Titan
Vaxart (VXRT) Completes Enrollment for Phase 1 Norovirus Vaccine Trial | VXRT Stock News - GuruFocus
Vaxart Completes Enrollment In Phase 1 Trial For Its Norovirus Oral Pill Vaccine Candidate - marketscreener.com
Vaxart completes enrollment for oral norovirus vaccine trial By Investing.com - Investing.com India
Vaxart completes enrollment for oral norovirus vaccine trial - Investing.com
Vaxart's Novel Oral Norovirus Vaccine Hits Major Milestone: Phase 1 Trial Fully Enrolled, Data Coming Mid-2025 - Stock Titan
Vaxart resumes BARDA-funded trial activities By Investing.com - Investing.com Canada
Vaxart says it can resume next-gen Covid work, will screen participants for oral vaccine trial - Endpoints News
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Federal government lifts hold on Peninsula biotech company's vaccine trialSan Francisco Business Times - The Business Journals
Vaxart resumes BARDA-funded trial activities - Investing.com
Vaccine biotechs say they’ve been told to stop next-gen Covid work under a Biden-era project - Endpoints News
Biota Pharmaceuticals to Present at Stifel 2015 Healthcare Conference - marketscreener.com
Vaxart to Present at World Vaccine Congress Washington 2025 on April 23 - GlobeNewswire
Revolutionary Oral Tablet Vaccines: Vaxart Reveals Latest Breakthrough Data at Major Congress - Stock Titan
Nasal Vaccines Market Top Companies StudyVaxart, Inc, FluGen Inc, Altimmune, Inc, Sinovac Biotech Ltd. - openPR.com
Proprietary - Vaxart Inc.
VXRT stock touches 52-week low at $0.31 amid market challenges - Investing.com Australia
VXRT stock touches 52-week low at $0.31 amid market challenges By Investing.com - Investing.com South Africa
RFK Jr. pauses $240 million contract for new ‘oral COVID vaccine’ - Todayville
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates - MSN
Vaxart reports inducement grants under Nasdaq listing rule - TipRanks
Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges - Investing.com
Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges By Investing.com - Investing.com South Africa
Vaxart Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vaxart's Major Talent Investment: 659,500 Share Awards and Key Executive Hire Signals Growth - Stock Titan
B. Riley Cuts Price Target on Vaxart to $2 From $2.50, Keeps Buy Rating - MarketScreener
Vaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call Transcript - Insider Monkey
Vaxart Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Oral - Vaxart Inc.
Sudden Trump administration order prompts Bay Area company to lay off staff - SFGATE
Bay Area biotech company lays off staff over sudden Trump admin order - SFGATE
Vaxart Inc to offer up to $50 mln of common stock -March 21, 2025 at 04:42 pm EDT - MarketScreener
RFK Jr. paused this Peninsula company's half-billion-dollar vaccine contract, then it cut jobs - The Business Journals
Vaxart Inc (VXRT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):